FMS Fresenius Medical Care AG

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

 

Pursuant to Rule 13a-16 or 15d-16 of the

Securities Exchange Act of 1934

 

For the month of May 2024

 

Commission file number: 001-32749

 

FRESENIUS MEDICAL CARE AG

(Translation of registrant's name into English)

 

Else-Kröner Strasse 1

61346 Bad Homburg

Germany

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  x                     Form 40-F ¨

 

 

 

EXHIBITS

 

The following exhibits are being furnished with this Report:

 

Exhibit 99.1

Press Release issued on May 16, 2024.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

DATE: May 16, 2024

 

	Fresenius Medical Care AG
	By:	/s/ Helen Giza
	Name:	Helen Giza
	Title:	Chief Executive Officer and Chair of the Management Board

 

	By:	/s/ Martin Fischer
	Name:	Martin Fischer
	Title:	Chief Financial Officer and member of the Management Board

 

 

Exhibit 99.1

 

 

 

Press Release	Media Contact  Christine Peters  T +49 160 60 66 770  christine.peters@freseniusmedicalcare.com
	Contact for Analysts and Investors  Dr. Dominik Heger  T +49 6172 609 2601  dominik.heger@freseniusmedicalcare.com
	www.freseniusmedicalcare.com/de

 

Fresenius Medical Care Annual General Meeting: Company makes significant progress in its Transformation Efforts and confirms its ambitious 2024 Growth Targets

 

·

Today's Annual General Meeting was the first one following the change in legal form completed in November 2023

 

·

Shareholders voted in favor of the proposed dividend of 1.19 euros, representing an increase of around 6 percent compared to the previous year

 

·

New compensation system for Management Board approved

 

·

Ambitious growth targets for 2024 confirmed

 

Bad Homburg (May 16, 2024) Fresenius Medical Care (FME), the global leader in providing products and services for people with kidney diseases, is executing its strategic turnaround plan and is well on track to achieve its goals for 2024.

 

At today's Annual General Meeting, Michael Sen, Chairman of the Supervisory Board of Fresenius Medical Care AG, said: "Fresenius Medical Care has made significant progress in 2023. The consistent implementation of the transformation program is beginning to pay off. The deconsolidation and the independence are providing Fresenius Medical Care with everything it needs to further strengthen its position in the dialysis market and to realize its full potential.”

 

Michael Sen added: “On behalf of the Supervisory Board, I would like to thank the members of the Management Board under the leadership of CEO Helen Giza for their trusting cooperation and very good performance in the past financial year. The newly composed management team has the necessary expertise, energy, and experience to take the company forward in the interests of patients, employees, and shareholders.”

 

 

Helen Giza, CEO of Fresenius Medical Care AG, said: “For 2023, we delivered top- and bottom-line growth, and exceeded our operating income outlook that we raised twice. Our FME25 transformation program is ahead of schedule and our portfolio optimization program is well underway. All our achievements mark a highly successful conclusion to an exceptional year of transformation and turnaround efforts.”

 

“Turning to 2024, this year is being spent in singular focus on disciplined execution and value creation. While 2023 was a year of level-setting, 2024 is one of momentum-building,” said Giza. The CEO thanked employees for their dedication and commitment to ensuring high-quality care for patients worldwide.

 

A significant majority of 96.97 percent of shareholders approved the dividend proposal for fiscal year 2023 of 1.19 euros, representing an increase of around 6 percent compared to the previous year (2022: 1.12 euros). The proposal aligns with the dividend policy of the company to adjust payouts according to Group net income development (excluding special items).

 

The shareholders also approved, with a majority of 87.58 percent, the new Management Board’s compensation system.

 

With a majority of 99.49 percent, the shareholders also approved the update to the Supervisory Board’s remuneration.

 

The Management Board and the Supervisory Board were discharged for the year 2023 with majorities of 98.71 percent and 98.42 percent, respectively.

 

At the Annual General Meeting, 88.39 percent of the share capital was represented.

 

About Fresenius Medical Care:

 

Fresenius Medical Care is the world's leading provider of products and services for people with kidney diseases, of whom approximately 4.1 million patients worldwide receive regular dialysis treatment. Through its network of 3,862 dialysis centers, Fresenius Medical Care provides dialysis treatment for approximately 325,000 patients worldwide and is the leading provider of dialysis products such as dialysis machines and dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and the New York Stock Exchange (FMS).

 

For further information, please visit www.freseniusmedicalcare.com/de.

 

Legal Disclaimer:

 

This communication contains forward-looking statements, which are subject to various risks and uncertainties. Future results may differ significantly from the currently expected results due to various factors such as changes in the business, economic, and competitive situation, changes in laws, regulatory approvals, the impact of the Covid-19 pandemic, results of clinical studies, exchange rate fluctuations, uncertainties regarding litigation or investigative proceedings, and the availability of financial resources. These and other risks and uncertainties are described in detail in the reports of Fresenius Medical Care AG filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG assumes no obligation to update the forward-looking statements contained in this communication.

 

 

---